Metformin HCL Tablets Manufacturer in India

Strava Healthcare is of the renowned manufacturer and supplier of metformin HCL tablets in India majorly for pharmaceutical distributors, hospital pharmacies, and export markets. Metformin has been initial line for type 2 diabetes since decades. It assists in lowering down hepatic glucose output, and does not cause hypoglycaemia on its own, and foremost thing is it does not contribute to weight gain, and its cardiovascular safety record holds up better than most of the newer agents. It is also in the list of WHO Essential Medicines. Metformin is more in demand in LATAM market like Costa Rica, Ecuador, Guatemala, Honduras as well as in African counties like Nigeria, Kenya, Tanzania, Angola, Mali, Ivory coast, Senegal, Ghana, Burundi and ASEAN countries like Myanmar and Cambodia.

 

Both instant release and extended acting formulations are there. All batches are GMP-produced with full analytical documentation.

Indications

  • Type 2 diabetes mellitus initial pharmacotherapy
  • Insulin tolerance and pre diabetes off-label but common in practice
  • Polycystic ovary syndrome menstrual regulation and fertility
  • Weight management in metabolic syndrome adjunctive use

For B2B and Pharma Partners

  • Contract manufacturing: IR and ER formulations, custom branding and pack sizes
  • Private label: market-ready metformin tablets
  • Bulk supply for domestic distributors and regulated export markets

Product Specifications

Parameter Details

Active Ingredient

Metformin hydrochloride

Strengths

500 mg / 850 mg / 1000 mg (IR); 500 mg / 750 mg / 1000 mg (ER)

Dosage Form

Film-coated tablet (IR) / Extended-release tablet (ER)

Packaging Sizes

Blisters of 10s, 15s; bottles of 100s, 500s

Storage

Below 30°C, away from moisture

Shelf Life

36 months

Manufacturer

Strava Healthcare Private Limited

Frequently Asked Questions

Metformin slows down intestinal glucose absorption and it changes gut microbiota composition those two things together are the most likely explanation for the nausea, loose stools, and abdominal discomfort that show up in the first few weeks. Starting at a low dose and titrating gradually helps. Taking it with food helps more. Patients who still cannot tolerate the IR version usually manage better on extended-release.
Low, when the drug is used in appropriate patients. The situations that raise the risk meaningfully are significant renal impairment — eGFR below 30 — liver failure, and anything causing tissue hypoxia. It should be withheld before contrast procedures and reconsidered during acute illness.
Yes. ER formulations in 500 mg, 750 mg, and 1,000 mg. Slower release means less GI burden and makes once-daily dosing workable for patients who struggle to stay on the standard version.
Scroll to Top